Carolyn Glass
Positions:
Associate Professor of Pathology
Pathology
School of Medicine
Member of the Duke Cancer Institute
Duke Cancer Institute
School of Medicine
Education:
M.D. 2007
University of Texas Medical Branch, School of Medicine
Ph.D. 2014
University of Rochester
Resident Physician, Vascular Surgery, Department Of Surgery
University of Rochester
Resident Physician, Anatomic Pathology, Harvard Medical School
Brigham and Women's Hospital
Cardiothoracic Pathology Fellow, Harvard Medical School
Brigham and Women's Hospital
Thoracic Pathology Fellow
University of Texas Southwestern Medical Center, Medical School
Grants:
Epithelioid Mechanisms of Sarcoidosis
Administered By
Institutes and Centers
Awarded By
Ann Theodore Foundation
Role
Collaborator
Start Date
End Date
Increasing the Diagnostic Accuracy of Antibody Mediated
Administered By
Institutes and Centers
Awarded By
CareDx, Inc.
Role
Co Investigator
Start Date
End Date
Turek - Step 2 Project
Administered By
Surgery, Cardiovascular and Thoracic Surgery
Awarded By
Enzyvant
Role
Investigator
Start Date
End Date
Publications:
Ex Vivo Gene Delivery to Porcine Cardiac Allografts Using a Myocardial-Enhanced Adeno-Associated Viral Vector.
Transplantation, the gold standard intervention for organ failure, is a clinical field that is ripe for applications of gene therapy. One of the major challenges in applying gene therapy to this field is the need for a method that achieves consistent and robust gene delivery to allografts. Normothermic ex vivo perfusion is a growing organ preservation method and a device for cardiac preservation was recently approved by the Food and Drug Administration (FDA) (Organ Care System, OCS™; TransMedics, Inc., Andover, MA); this device maintains donor hearts in a near physiologic state while they are transported from the donor to the recipient. This study describes the administration of recombinant adeno-associated viral vectors (rAAVs) during ex vivo normothermic perfusion for the delivery of transgenes to porcine cardiac allografts. We utilized a myocardial-enhanced AAV3b variant, SASTG, assessing its transduction efficiency in the OCS perfusate relative to other AAV serotypes. We describe the use of normothermic ex vivo perfusion to deliver SASTG carrying the Firefly Luciferase transgene to porcine donor hearts in four heterotopic transplant procedures. Durable and dose-dependent transgene expression was achieved in the allografts in 30 days, with no evidence of off-target transgene expression. This study demonstrates the feasibility and efficiency of delivering genes to a large animal allograft utilizing AAV vectors during ex vivo perfusion. These findings support the idea of gene therapy interventions to enhance transplantation outcomes.
Authors
MLA Citation
Mendiola Pla, Michelle, et al. “Ex Vivo Gene Delivery to Porcine Cardiac Allografts Using a Myocardial-Enhanced Adeno-Associated Viral Vector.” Hum Gene Ther, vol. 34, no. 7–8, Apr. 2023, pp. 303–13. Pubmed, doi:10.1089/hum.2022.241.
URI
https://scholars.duke.edu/individual/pub1569282
PMID
36927038
Source
pubmed
Published In
Hum Gene Ther
Volume
34
Published Date
Start Page
303
End Page
313
DOI
10.1089/hum.2022.241
NIH SenNet Consortium to map senescent cells throughout the human lifespan to understand physiological health.
Cells respond to many stressors by senescing, acquiring stable growth arrest, morphologic and metabolic changes, and a proinflammatory senescence-associated secretory phenotype. The heterogeneity of senescent cells (SnCs) and senescence-associated secretory phenotype are vast, yet ill characterized. SnCs have diverse roles in health and disease and are therapeutically targetable, making characterization of SnCs and their detection a priority. The Cellular Senescence Network (SenNet), a National Institutes of Health Common Fund initiative, was established to address this need. The goal of SenNet is to map SnCs across the human lifespan to advance diagnostic and therapeutic approaches to improve human health. State-of-the-art methods will be applied to identify, define and map SnCs in 18 human tissues. A common coordinate framework will integrate data to create four-dimensional SnC atlases. Other key SenNet deliverables include innovative tools and technologies to detect SnCs, new SnC biomarkers and extensive public multi-omics datasets. This Perspective lays out the impetus, goals, approaches and products of SenNet.
Authors
SenNet Consortium,
MLA Citation
SenNet Consortium, Daxin. “NIH SenNet Consortium to map senescent cells throughout the human lifespan to understand physiological health.” Nat Aging, vol. 2, no. 12, Dec. 2022, pp. 1090–100. Pubmed, doi:10.1038/s43587-022-00326-5.
URI
https://scholars.duke.edu/individual/pub1561272
PMID
36936385
Source
pubmed
Published In
Nature Aging
Volume
2
Published Date
Start Page
1090
End Page
1100
DOI
10.1038/s43587-022-00326-5
Tensorial tomographic differential phase-contrast microscopy
We report Tensorial Tomographic Differential Phase-Contrast microscopy (T2DPC), a quantitative label-free tomographic imaging method for simultaneous measurement of phase and anisotropy. T2DPC extends differential phase-contrast microscopy, a quantitative phase imaging technique, to highlight the vectorial nature of light. The method solves for permittivity tensor of anisotropic samples from intensity measurements acquired with a standard microscope equipped with an LED matrix, a circular polarizer, and a polarization-sensitive camera. We demonstrate accurate volumetric reconstructions of refractive index, birefringence, and orientation for various validation samples, and show that the reconstructed polarization structures of a biological specimen are predictive of pathology.
MLA Citation
Xu, S., et al. “Tensorial tomographic differential phase-contrast microscopy.” Ieee International Conference on Computational Photography, Iccp 2022, 2022. Scopus, doi:10.1109/ICCP54855.2022.9887674.
URI
https://scholars.duke.edu/individual/pub1555357
Source
scopus
Published In
Ieee International Conference on Computational Photography, Iccp 2022
Published Date
DOI
10.1109/ICCP54855.2022.9887674
Transvenous Endomyocardial Biopsy Technique for Intra-abdominal Heterotopic Cardiac Grafts.
The porcine intra-abdominal heterotopic heart transplantation model allows for the assessment of immunologic effects on cardiac transplantation without relying on the allograft to maintain hemodynamic support for the animal. Historically, allograft function and histology is monitored by physical exam, echocardiogram evaluation, percutaneous core biopsy, and open biopsy. We performed transvenous endomyocardial biopsies in three pigs that had undergone heterotopic heart implantation. We describe the procedure to be feasible and reproducible, and that histologic results from these biopsies correlated with those from corresponding tissue collected by surgical dissection at the time of allograft explantation. The ability to perform endomyocardial biopsies in the heterotopic heart transplantation model allows for serial non-invasive monitoring of allograft histology.
Authors
MLA Citation
Mendiola Pla, Michelle, et al. “Transvenous Endomyocardial Biopsy Technique for Intra-abdominal Heterotopic Cardiac Grafts.” J Cardiovasc Transl Res, Nov. 2022. Pubmed, doi:10.1007/s12265-022-10337-7.
URI
https://scholars.duke.edu/individual/pub1555867
PMID
36344902
Source
pubmed
Published In
J Cardiovasc Transl Res
Published Date
DOI
10.1007/s12265-022-10337-7
Chronological trends in the causation of malignant mesothelioma: Fiber burden analysis of 619 cases over four decades.
Malignant mesothelioma is a relatively rare malignancy with a strong association with prior asbestos exposure. A percentage of cases is not related to asbestos, and fiber analysis of lung tissue is a useful methodology for identifying idiopathic or spontaneous cases. We have performed fiber analyses in more than 600 cases of mesothelioma over the past four decades and were interested in looking for trends in terms of fiber types and concentrations as well as percentages of cases not related to asbestos. Demographic information was also considered including patient age, gender, and tumor location (pleural vs. peritoneal). The histologic pattern of the tumor and the presence or absence of pleural plaques or asbestosis were noted. Fiber analysis was performed in 619 cases, using the sodium hypochlorite technique for digestion of lung tissue samples. Asbestos bodies were counted by light microscopy (LM) and coated and uncoated fibers by scanning electron microscopy (EM). The results were stratified over four decades. Trends that were observed included increasing patient age, increasing percentage of women, increasing percentage of peritoneal cases, and increasing percentage of epithelial histological type. There was a decreasing trend in the percentage of patients with concomitant asbestosis (p < 0.001). The percentage of cases with an elevated lung asbestos content decreased from 90.5% in the 1980s to 54.1% in the 2010s (p < 0.001). This trend also held when the analysis was limited to 490 cases of pleural mesothelioma in men (91.8% in the 1980s vs. 65.1% in the 2010s). There was a decrease in the median asbestos body count by LM from 1390 asbestos bodies per gram of wet lung in the 1980s to 38 AB/gm in the 2010s. Similar trends were observed for each of the asbestos fiber types as detected by EM. We conclude that there has been a progressive decrease in lung fiber content of mesothelioma patients during the past four decades, with an increasing percentage of cases not related to asbestos and an increase in median patient age.
Authors
Roggl, VL; Green, CL; Liu, B; Carney, JM; Glass, CH; Pavlisko, EN
MLA Citation
Roggl, Victor L., et al. “Chronological trends in the causation of malignant mesothelioma: Fiber burden analysis of 619 cases over four decades.” Environ Res, Nov. 2022, p. 114530. Pubmed, doi:10.1016/j.envres.2022.114530.
URI
https://scholars.duke.edu/individual/pub1569911
PMID
36965800
Source
pubmed
Published In
Environ Res
Published Date
Start Page
114530
DOI
10.1016/j.envres.2022.114530

Associate Professor of Pathology
Contact:
214D Davison Building, 40 Duke Medicine Circle, Box #3712 Duhs, Durham, NC 27710